ALK fusion gene positive lung cancer and 3 cases treated with an inhibitor for ALK kinase activity
Hideki Kimura, Akira Nakagawara(Asia Centre), Miki Ohira(Saitama Cancer Center), Masato Shingyoji(Chiba Cancer Center), Takahiro Nakajima(University Health Network), Kengo Takeuchi(Japanese Foundation For Cancer Research), Meiji Itakura(Chiba Cancer Center), Hiroyuki Mano(National Cancer Research Institute), Makiko Itami(Chiba Cancer Center), Toshihiko Iizasa(Chiba Cancer Center), Sana Yokoi(Chiba Cancer Center), Yukiko Matsui, Mitsuru Yoshino(National Hospital Organization), Dai Ikebe(Chiba Cancer Center), Manabu Soda(The University of Tokyo), Hajime Kageyama(Chiba Cancer Center)
Cited by 32
Related Papers
Lactic acid promotes PD-1 expression in regulatory T cells in highly glycolytic tumor microenvironments
|Cancer Cell|2022|828
The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies
|Nature Immunology|2020|810
Role of p53 in Cell Death and Human Cancers
|Cancers|2011|728
International consensus for neuroblastoma molecular diagnostics: report from the International Neuroblastoma Risk Group (INRG) Biology Committee
|British Journal of Cancer|2009|404
Transcriptional landscape of B cell precursor acute lymphoblastic leukemia based on an international study of 1,223 cases
|Proceedings of the National Academy of Sciences|2018|324